Connect your AI

Castle Biosciences CSTL Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

FMC CorporationFMC

$1.9M-80.4%

APO

Apogee EnterprisesAPOG

$3.2M+216%

VestisVSTS

$4.2M—

HTF

Heartflow, Inc. Common StockHTFL

$912K+15,100%

AMC Networks Inc.AMCX

$4.37M+169%

Taboola.com Ltd.TBLA

$617K-67.4%

Other financials

Income statement

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Castle Biosciences's capital investments accrued but not yet paid?: Castle Biosciences (CSTL) reported capital investments accrued but not yet paid of $4.1M in Q1 2026.
How has Castle Biosciences's capital investments accrued but not yet paid changed year-over-year?: Castle Biosciences's capital investments accrued but not yet paid increased by 27.4% year-over-year, from $3.22M to $4.1M.